PDMP Blocks Brefeldin A–induced Retrograde Membrane Transport from Golgi to ER: Evidence for Involvement of Calcium Homeostasis and Dissociation from Sphingolipid Metabolism by Kok, Jan Willem et al.
 
ã
 
 The Rockefeller University Press, 0021-9525/98/07/25/14 $2.00
The Journal of Cell Biology, Volume 142, Number 1, July 13, 1998 25–38
http://www.jcb.org 25
 
PDMP Blocks Brefeldin A–induced Retrograde Membrane Transport from
Golgi to ER: Evidence for Involvement of Calcium Homeostasis and
Dissociation from Sphingolipid Metabolism
 
Jan Willem Kok,* Teresa Babia,
 
§
 
 Catalin M. Filipeanu,
 
‡
 
 Adriaan Nelemans,
 
‡
 
 Gustavo Egea,
 
§
 
and Dick Hoekstra*
 
*Department of Physiological Chemistry, 
 
‡
 
Department of Clinical Pharmacology, University of Groningen, Groningen Institute 
for Drug Studies (GIDS), 9713 AV Groningen, The Netherlands; and 
 
§
 
Universitat de Barcelona, Facultat de Medicina, 
Departament de Biologia Cellular, Institut d’Investigacions Biomediques August Pi I Sunyer, 08036 Barcelona, Spain
 
Abstract. 
 
In this study, we show that an inhibitor of 
 
sphingolipid biosynthesis, 
 
d
 
,
 
l
 
-
 
threo
 
-1-phenyl-2-
decanoylamino-3-morpholino-1-propanol (PDMP), in-
hibits brefeldin A (BFA)-induced retrograde mem-
brane transport from Golgi to endoplasmic reticulum 
(ER). If BFA treatment was combined with or preceded 
by PDMP administration to cells, disappearance of dis-
crete Golgi structures did not occur. However, when 
BFA was allowed to exert its effect before PDMP addi-
tion, PDMP could not “rescue” the Golgi compartment.
Evidence is presented showing that this action of 
PDMP is indirect, which means that the direct target is 
not sphingolipid metabolism at the Golgi apparatus. A 
fluorescent analogue of PDMP, 6-(
 
N
 
-[7-nitro-2,1,3-
 
benzoxadiazol-4-yl]amino)hexanoyl-PDMP (C
 
6
 
-NBD-
PDMP), did not localize in the Golgi apparatus. More-
over, the effect of PDMP on membrane flow did not 
correlate with impaired C
 
6
 
-NBD-sphingomyelin bio-
synthesis and was not mimicked by exogenous C
 
6
 
-cera-
mide addition or counteracted by exogenous C
 
6
 
-gluco-
sylceramide addition. On the other hand, the PDMP 
effect was mimicked by the multidrug resistance pro-
tein inhibitor MK571.
The effect of PDMP on membrane transport corre-
lated with modulation of calcium homeostasis, which 
occurred in a similar concentration range. PDMP re-
leased calcium from at least two independent calcium 
stores and blocked calcium influx induced by either ex-
tracellular ATP or thapsigargin. Thus, the biological ef-
fects of PDMP revealed a relation between three im-
portant physiological processes of multidrug resistance, 
calcium homeostasis, and membrane flow in the ER/
Golgi system.
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l
 
-
 
threo
 
-1-
 
phenyl
 
-2-
 
decanoylamino
 
-3-
 
morpholino
 
-  1-
 
propanol
 
 (PDMP)
 
1
 
 is a well-known inhibitor of
sphingolipid biosynthesis (Radin et al., 1993). The
formation of glucosylceramide (GlcCer) is drastically in-
hibited by PDMP, while the effect on sphingomyelin bio-
synthesis appears to depend on the cell type and the con-
centration of the drug. In addition, PDMP treatment may
lead to an accumulation of the endogenous sphingolipid
precursor ceramide (Cer).
Apart from its effect on sphingolipid synthesis, PDMP
has been shown to inhibit anterograde membrane trans-
port through the Golgi complex and from the Golgi com-
plex to the plasma membrane (Rosenwald et al., 1992). A
similar effect was observed when cells were incubated with
a short-chain analogue of Cer, C
 
6
 
-Cer (Rosenwald and Pa-
gano, 1993). This suggests that PDMP-induced inhibition
of anterograde membrane transport may (in part) be a re-
sult of an elevation of the intracellular Cer level.
In this study, we investigated the effect of PDMP on
brefeldin A (BFA)-induced retrograde membrane trans-
port from Golgi to ER. The formation of transport vesicles
involved in retrograde trafficking, as well as anterograde,
has been extensively studied at the molecular level (Ari-
dor and Balch, 1996; Bednarek et al., 1996). Assembly of
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1. 
 
Abbreviations used in this paper
 
: BFA, brefeldin A; Cer, ceramide; C
 
6
 
-
NBD, 6-(
 
N
 
-[7-nitro-2,1,3-benzoxadiazol-4-yl]amino)hexanoyl or hexanoic
acid; GlcCer, glucosylceramide; ManII, mannosidase II; MDR, multidrug
resistance; MRP, multidrug resistance protein; NRK, normal rat kidney;
PDMP, 
 
d
 
,
 
l
 
-
 
threo
 
-1-phenyl-2-decanoylamino-3-morpholino-1-propanol;
P-gp, P-glycoprotein; SM, sphingomyelin.
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coats is thought to provide the driving force for vesicle
budding. Two distinct vesicle coats, COPI and COPII, are
involved in retrograde and anterograde trafficking, respec-
tively. COPI, a cytosolic protein consisting of seven sub-
units, is recruited to the target membrane after activation
and binding of the small GTP-binding protein ARF1.
Treatment of cells with BFA is known to interfere with
coat assembly (Scheel et al., 1997) and results in retro-
grade merging of Golgi membranes with the ER (Lippin-
cott et al., 1989; Klausner et al., 1992). BFA blocks the
assembly of coated vesicles by inhibiting GTP/GDP ex-
change on ARF1 (Donaldson et al., 1992; Helms and
Rothman, 1992), thus preventing the binding of ARF and
coatomer to Golgi membranes. Golgi membrane tubula-
tion and absorption into the ER follows COPI dissociation
from membranes (Sciaky et al., 1997). It is assumed that
this proceeds via direct (i.e., uncoupled from vesicle bud-
ding) fusion reactions between Golgi membranes as well
as between Golgi and ER membranes (Elazar et al., 1994).
ARF and coatomer thus prevent direct fusion between
membranes and provide a molecular mechanism for con-
trolled transfer of cargo between compartments through
vesicular carriers. In line with this, coat disassembly occurs
before fusion with the target membrane when ARF is trig-
gered to hydrolyze bound GTP (Tanigawa et al., 1993). It
is not known whether uncoupled fusion occurs physiologi-
cally, i.e., without BFA, but it is not likely to be involved
in signal-dependent retrograde transport of KDEL-bear-
ing proteins from (the plasma membrane via) the Golgi to
the ER (Johannes et al., 1997; Cole et al., 1998). In this
study, we show that PDMP inhibits the disassembly of the
Golgi complex and its merging with the ER compartment
in BFA-treated cells. This was assessed by staining of the
Golgi apparatus using two approaches. One involved
Golgi staining in fixed cells, using antibodies to a 
 
cis
 
-Golgi
resident protein, mannosidase II (ManII), and a 
 
trans
 
-
Golgi resident protein, GMP
 
t-1
 
 (Alcalde et al., 1992, 1994).
The other approach involved the use of 6-(
 
N
 
-[7-nitro-
2,1,3-benzoxadiazol-4-yl]amino)hexanoyl-Cer (C
 
6
 
-NBD-
Cer), a well-known Golgi marker (Lipsky and Pagano,
1985; Pagano, 1989), which offers the advantage of study-
ing Golgi morphology in intact, living cells. Furthermore,
sphingolipid metabolism can be monitored concomitantly,
since in the Golgi conversion of C
 
6
 
-NBD-Cer to C
 
6
 
-NBD-
sphingomyelin (SM) and C
 
6
 
-NBD-glycolipids occurs. We
conclude that PDMP inhibits BFA-induced retrograde
Golgi to ER membrane flow in various cell types, since
both newly synthesized sphingolipids and Golgi resident
proteins were retained in discrete Golgi structures in
BFA-treated cells. Evidence is provided for an indirect
mechanism of action of PDMP, involving modulation of
calcium homeostasis and interaction with multidrug resis-
tance (MDR) proteins.
 
Materials and Methods
 
Materials
 
d
 
-sphingosine, BFA, cyclosporin A, thapsigargin, and E3A5 mouse mono-
clonal anti–
 
b
 
-COP antibody were obtained from Sigma Chemical Co. (St.
Louis, MO). The succinimidyl ester of C
 
6
 
-NBD. Bodipy™-503/512-C
 
5
 
,
and indo-1-HS/AM were from Molecular Probes (Eugene, OR). PDMP,
 
d,l
 
-
 
threo
 
-lyso-PDMP, C
 
6
 
-Cer, and 1-
 
b
 
-
 
d
 
-glucosylsphingosine were pur-
 
chased from Matreya, Inc. (Pleasant Gap, PA). TRITC/FITC anti–rabbit/
mouse IgG F(ab
 
9
 
)
 
2
 
 fragments and ATP were from Boehringer Mannheim
GmbH (Mannheim, Germany). MK571 and PSC833 were kind gifts from
Dr. E. Vellenga (University of Groningen, the Netherlands). Anti-ManII
polyclonal antibodies were kindly provided by Dr. A. Velasco (University
of Sevilla, Spain), and anti-GMP
 
t-1
 
 antibodies were provided by Dr. I. San-
doval (Centro de Biologia Molecular Severo Ochoa, Consejo Superior de
Investigaciones Cientificas, Universidad Autonoma de Madrid, Spain).
 
Cell Culture
 
Monocultures of HT29 G
 
1
 
 or normal rat kidney (NRK) cells were grown
in Dulbecco’s minimal essential medium (DME, containing 25 mM glu-
cose), supplemented with 10% (vol/vol) decomplemented (56
 
8
 
C, 30 min)
FCS, in a water-saturated atmosphere of 5% CO
 
2
 
/95% air. During the ex-
ponential phase of growth, the culture medium was changed every 48 h.
For maintenance purposes, cells were trypsinized once (HT29) or twice
(NRK) a week and plated at appropriate densities to obtain confluent lay-
ers after 1 wk of culture.
 
C
 
6
 
-(NBD-)sphingolipid Synthesis and
Incubation Conditions
 
(Fluorescent) short-chain sphingolipids/PDMP were synthesized accord-
ing to Kok and Hoekstra (1993). C
 
6
 
-NBD-Cer and C
 
6
 
-NBD-PDMP were
synthesized from 
 
d
 
-
 
erythro
 
-sphingosine and 
 
d,l
 
-
 
threo
 
-lyso-PDMP,
respectively, and the succinimidyl ester of C
 
6
 
-NBD. C
 
5
 
-Bodipy-Cer was
synthesized from 
 
d
 
-
 
erythro
 
-sphingosine and Bodipy™-503/512-C
 
5
 
. C
 
6
 
-
GlcCer was synthesized from 1-
 
b
 
-
 
d
 
-glucosylsphingosine and hexanoic
acid. For cell incubations, C
 
6
 
-(NBD-)sphingolipid/PDMP solutions were
made by ethanol injection in serum-free culture medium (0.5% [vol/vol]
final ethanol concentration; see also Kok et al., 1992).
 
Lipid Extraction and Analysis
 
Approximately 10
 
7
 
 HT29 G
 
1
 
 or NRK cells were incubated with 10 
 
m
 
M
C
 
6
 
-NBD-Cer for 60 min at 37
 
8
 
C. After these incubations, the cells to-
gether with the incubation medium were subjected to lipid extraction by
the procedure of Bligh and Dyer (1959). C
 
6
 
-NBD-sphingolipids were sep-
arated by high performance thin layer chromatography (HPTLC) using
CH
 
3
 
Cl/CH
 
3
 
OH/20% (wt/vol) NH
 
4
 
OH (14:6:1, vol/vol/vol) as the running
solvent system. Individual C
 
6
 
-NBD-sphingolipid species (Cer, GlcCer,
and SM) were scraped from the HPTLC plates and eluted from the silica
with 1% (vol/vol) Triton X-100 by vigorous shaking at 37
 
8
 
C. Individual
C
 
6
 
-NBD-sphingolipid species were quantified by measuring the NBD flu-
orescence in a fluorimeter at an excitation wavelength of 465 nm and an
emission wavelength of 530 nm.
 
Measurement of C
 
6
 
-NBD-PDMP Uptake, Efflux, and 
Accessibility to Sodium Dithionite
 
Approximately 10
 
7
 
 HT29 G
 
1
 
 cells were washed with Hanks’ solution and
incubated with 10 
 
m
 
M C
 
6
 
-NBD-PDMP for 30 min at 37
 
8
 
C. The incubation
buffer was aspirated and replaced by fresh Hanks’ solution, followed by
incubations at 37
 
8
 
C for various time intervals. At each time point, both the
cell fraction and the incubation medium were subjected to lipid extraction
(see above). The amount of C
 
6
 
-NBD-PDMP in each fraction was mea-
sured in a fluorimeter as described above. In all experiments, mock-
treated cells were subjected to lipid extraction and fluorescence measure-
ment. These background values were subtracted from the values of cells,
which had been incubated with C
 
6
 
-NBD-PDMP.
For sodium dithionite quenching studies, the initial 37
 
8
 
C incubation
with 10 
 
m
 
M C
 
6
 
-NBD-PDMP was followed by a 30-min incubation in
Hanks’ solution containing 30 mM Na
 
2
 
S
 
2
 
O
 
4
 
 (diluted from a stock solution
of 1 M Na
 
2
 
S
 
2
 
O
 
4
 
 in 1 M Tris, pH 10; c.f. McIntyre and Sleight, 1991). Con-
trol cells were incubated in Hanks’ solution without sodium dithionite. To
study the effect of sodium dithionite on C
 
6
 
-NBD-Cer, cells were incubated
with 10 
 
m
 
M C
 
6
 
-NBD-Cer for 30 min at 37
 
8
 
C, followed by a “back-
exchange” at 2
 
8
 
C. To this end, cells were incubated with 5% (wt/vol) BSA
in Hanks’ solution for 30 min at 2
 
8
 
C, followed by extensive washing.
Thereafter, cells were incubated in Hanks’ solution with or without 30
mM Na
 
2
 
S
 
2
 
O
 
4
 
 for 30 min at 37
 
8
 
C, followed by a back-exchange at 2
 
8
 
C.
Back-exchanges were performed to ensure that plasma membrane pools
of C
 
6
 
-NBD-lipid did not contribute to the measured values in control
cells. These pools consist of C
 
6
 
-NBD-Cer, which was initially inserted in 
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the plasma membrane, and/or C
 
6
 
-NBD-sphingolipid products, which were
synthesized in the Golgi apparatus and transported to the plasma mem-
brane. In cells subjected to dithionite, quenching of this pool of C
 
6
 
-NBD-
lipid will occur. In contrast to the experiments with C
 
6
 
-NBD-Cer, in the
case of C
 
6
 
-NBD-PDMP, similar results were obtained, regardless of
whether the back-exchange had been carried out.
In all experiments, total lipid phosphorus was determined in each frac-
tion after perchloric acid destruction according to Böttcher et al. (1961).
In addition, in cell fractions the number of cells was counted. All C
 
6
 
-NBD-
PDMP/Cer determinations were normalized to total lipid phosphorus.
 
Fluorescence Microscopy
 
Cells were grown on glass coverslips contained in 35-mm-diam Petri
dishes. Experiments were carried out 72 h after passage. Before experi-
ments, the cells were cooled (30 min) and washed several times with ice-
cold Hanks’ solution. Cells were incubated with C
 
6
 
-NBD-Cer (5 
 
m
 
M) in
Hanks’ solution at 2
 
8
 
C for 1 h, followed by a wash with Hanks’ buffer.
Subsequently, the cells were subjected to 30-min incubations with Hanks’
solution, containing 5 
 
m
 
g/ml BFA, 100 
 
m
 
M (lyso-)PDMP, or both, at 37
 
8
 
C.
Occasionally, either C
 
6
 
-Cer or C
 
6
 
-GlcCer (both 100 
 
m
 
M), or one of the
MDR inhibitors was included. Also during these incubations, C
 
6
 
-NBD-
Cer (2 
 
m
 
M) was present. Finally, a back-exchange was performed by incu-
bating the cells with 5% BSA in cold (2
 
8
 
C) Hanks’ solution for 30 min,
followed by extensive washing. In the case of intracellular PDMP localiza-
tion, cells were incubated with C
 
6
 
-NBD-PDMP (100 
 
m
 
M) in Hanks’ solu-
tion for 30 min at 37
 
8
 
C. The effect on Golgi morphology was in this case
monitored by using C5-Bodipy-Cer. For this purpose, cells were preincu-
bated with 5 mM C5-Bodipy-Cer for 60 min at 378C to ensure that high
enough concentrations of Bodipy-sphingolipids at the Golgi apparatus
were reached for a spectral shift in fluorescence to occur (Pagano et al.,
1991). For dithionite quenching, cells were incubated with Hanks’ solution
containing 30 mM Na2S2O4 (diluted from a stock solution of 1M Na2S2O4
in 1 M Tris, pH 10; c.f. McIntyre and Sleight, 1991) for 30 min at 378C, al-
lowing fluid-phase uptake of this NBD quencher in endocytic compart-
ments to occur. Hence, this procedure will result in loading of the endo/ly-
sosomal system with the NBD quencher (Kok et al., 1995).
For immunocytochemical studies, following various incubation
schemes with BFA and/or PDMP, cells were fixed in 2208C methanol for
30 min. Thereafter, cells were washed four times with PBS, followed by a
30-min incubation with PBS/1% (wt/vol) BSA. Fixed cells were incubated
overnight at 48C with the primary antibody diluted in PBS/1% (wt/vol)
BSA (anti-ManII: diluted 1:4,000 for NRK cells and 1:80 for HT29 G1
cells; 18B11: diluted 1:100), followed by two washes with PBS/1% (wt/vol)
BSA. Thereafter, fixed cells were incubated for 60 min at room tempera-
ture with the secondary antibody TRITC anti–rabbit IgG F(ab9)2 frag-
ment (dilution 1:30), followed by two washes with PBS/1% (wt/vol) BSA.
In case of double immunofluorescence staining, the cells were incubated
with two primary antibodies (anti-ManII and anti–b-COP: diluted 1:20)
overnight and subsequently with FITC anti–rabbit IgG F(ab9)2 fragment 1
TRITC anti–mouse IgG F(ab9)2 fragment (dilutions 1:30) for 60 min. Fi-
nally, fixed cells were mounted and examined by fluorescence microscopy.
Fluorescence microscopy was performed with an Olympus (Melville, NY)
AX-70 research microscope, equipped with a PM20 photomicrography
system. Photomicrographs were taken with 10-s (NBD fluorescence) or
1-min (FITC/TRITC fluorescence) exposure times using Ilford (Cheshire,
UK) HP5 film that was processed at 1,600 ASA. All images from HT29
cells were taken with a confocal scanning laser microscope (True Confocal
Scanner 4D; Leica, Heidelberg, Germany) equipped with an argon-kryp-
ton laser and coupled to a Leitz DM IRB inverted microscope (Leica).
Images were taken at 488 nm for NBD fluorescence and 562 nm for Bo-
dipy/TRITC fluorescence.
Calcium Measurements
Intracellular calcium concentrations were measured as described previ-
ously (Sipma et al., 1995; Filipeanu et al., 1997). After trypsinization, the
cells were suspended in Hanks’ solution at a concentration of 107 cells/ml.
The cells were incubated with 2 mM indo-1/AM at room temperature for
30 min in the dark. The cells were collected by centrifugation and washed
twice with Hanks’ solution before fluorescence measurements. Intracellu-
lar indo-1 fluorescence was measured in a spectrophotometer (model
Aminco®-Bowman; Spectronic Instruments, Inc., Rochester, NY), using
106 cells/ml for each measurement. Measurement was performed at 238C
to prevent dye compartmentalization and leakage. The excitation wave-
length was 349 nm, and emission at 410 and 490 nm were acquired with a
frequency of 1 Hz. Drugs were added with a Hamilton syringe to a mag-
netically stirred cell suspension in a volume ,1% of the total cell suspen-
sion volume (3 ml). Actual [Ca21]i values were calculated by a classical
equation (Grynkiewicz et al., 1985) using Rmax and Rmin values obtained at
the end of each experiment using 60 mg/ml saponin and 20 mM EGTA,
pH 8.0, respectively. Autofluorescence of the cells, i.e., the signal remain-
ing after 10 mM MnCl2 addition, was subtracted before calculation. Cal-
cium-free medium is defined as Hanks’ buffer to which 1.5 mM EGTA is
added (final [Ca21]i , 1 mM).
Results
PDMP Inhibits BFA-induced Retrograde Golgi to ER 
Lipid Flow in HT29 Cells
As shown in Fig. 1 B, incubation of HT29 G1 cells with
BFA resulted in loss of discrete Golgi structures that had
been labeled with C6-NBD-Cer (compare to control cells
in Fig. 1 A). However, when BFA incubation had been
preceded by PDMP treatment (Fig. 1 E), discrete Golgi
structures were still observed. Apparently, PDMP blocked
the BFA-induced retrograde C6-NBD-lipid flow from
Golgi to ER. The observed effects were critically depen-
dent on the order of addition of both drugs. Thus, when
BFA was allowed to act before PDMP was added to the
cells (Fig. 1 F), discrete Golgi structures were no longer
detectable, i.e., all Golgi membranes had already merged
with the ER compartment by BFA-induced retrograde
flow. In the case when both drugs were added simulta-
neously (Fig. 1 D), Golgi compartments did not disappear.
Inhibition of BFA-induced Retrograde Transport
by PDMP Is Not Restricted to Lipids; PDMP Blocks 
Membrane Flow
To investigate whether the effect of PDMP was specific
for (C6-NBD-)lipid flow or was due to a general block of
membrane flow, the following experiments were per-
formed. Cells were treated with BFA and/or PDMP, as in
Fig. 1, A–F, but instead of monitoring the fate of C6-NBD-
Cer in living cells, the localization of a Golgi resident pro-
tein was assessed after fixation of the cells. As shown in
Fig. 1, G–N, the fate of a cis/medial-Golgi resident protein,
ManII, was very similar to that observed for C6-NBD-Cer
in living cells. Indeed, BFA treatment (Fig. 1 H) caused a
loss of discrete Golgi structures, while PDMP resulted in
maintenance of the Golgi compartment, provided that it
had been administered before (Fig. 1 M) or together with
(Fig. 1 L) BFA. In conclusion, not only is BFA-induced
retrograde lipid flow inhibited by PDMP, but the entire
membrane flow is blocked.
Inhibition of BFA-induced Retrograde Membrane Flow 
by PDMP Is Not Restricted to HT29 Cells
The effect of PDMP on BFA-induced retrograde Golgi to
ER membrane flow was not a feature that occurred only in
the human HT29 G1 colon tumor cell line. In an entirely
different cell type, the NRK fibroblast, PDMP affected
BFA-induced retrograde membrane flow as well, as indi-
cated by either C6-NBD-Cer labeling (Fig. 2, A–F) or
ManII staining (Fig. 2, G–N). Note that when PDMP was
administered simultaneously with BFA in NRK cells (Fig.
2, D and L), the Golgi complex appeared swollen, whileThe Journal of Cell Biology, Volume 142, 1998 28
C6-NBD-lipid staining suggested the presence of tubules
(Fig. 2 D). These structural changes were not observed
when PDMP was allowed to exert its effect before BFA
addition. It thus appeared that PDMP interfered with the
ongoing redistribution of membranes into the ER, just af-
ter the onset of this process induced by BFA. A trans-
Golgi resident protein, GMPt-1 (Alcade et al., 1992, 1994),
was also affected by PDMP treatment (Fig. 2, P–V), al-
though in this case some residual Golgi structure was ob-
served in BFA-treated cells.
Characteristics of the PDMP block of BFA-induced 
Retrograde Membrane Flow
Although most experiments were performed at the time
scale of 1 h, the effect of PDMP on BFA-induced retro-
grade Golgi to ER membrane flow was also observed after
extended incubation time intervals. BFA 1 PDMP treat-
ment during 3 h did not result in disappearance of discrete
Golgi structures (Fig. 3 A; c.f. Fig. 2 L). When PDMP was
removed from the medium, its inhibiting effect on BFA-
induced retrograde membrane flow turned out to be re-
versible. After an initial incubation with PDMP 1 BFA
for 30 min (Fig. 3 B), a subsequent incubation with BFA
alone resulted in a gradual loss of discrete Golgi structures
(Fig. 3, C and D). Note that only 3 h after the withdrawal
of PDMP, the effect of BFA was completed.
The effect of PDMP on BFA-induced retrograde mem-
brane flow was concentration dependent. This was ob-
served when cells were incubated with PDMP at various
concentrations, ranging from 10 to 100 mM (in steps of
10 mM), followed by incubation with both PDMP (at the
respective concentrations) and BFA. In HT29 cells, the in-
hibition of BFA-induced retrograde membrane flow, as
monitored by C6-NBD-Cer staining, became apparent at a
PDMP concentration of 50 mM, although not all cells were
affected at this concentration. NRK cells appeared to be
slightly less sensitive, as inhibition became apparent at
80 mM. Furthermore, the inhibitory effect of PDMP re-
quired the intact molecule because lyso-PDMP, which
lacks the fatty-acyl moiety, was not able to block BFA-
induced retrograde membrane flow in both HT29 G1 and
NRK cells (Fig. 4).
PDMP Does Not Impair Coatomer Detachment 
Induced by BFA
BFA-induced dissociation of coatomer from membranes
Figure 1. PDMP inhibits BFA-induced retrograde membrane flow from Golgi to ER in HT29 cells. HT29 G1 cells, grown on coverslips,
were incubated for 30 min at 378C in Hanks’ solution (control; A and G) or in Hanks’ containing 5 mg/ml BFA (B and H), 100 mM PDMP
(C and K), or both BFA and PDMP (D and L). In E and M, the 30-min incubation with BFA 1 PDMP was preceded by a 30-min incuba-
tion with PDMP, while in F and N, it was preceded by a 30-min incubation with BFA. One series (A–F) shows living cells (pre-)incubated
with C6-NBD-Cer (see Materials and Methods). In the other series (G–N), cells were fixed after the incubations with inhibitors and pro-
cessed for immunocytochemical staining using an antibody against ManII. Images were taken with confocal scanning laser microscopy.
Bar, 10 mm.Kok et al. PDMP Blocks Golgi to ER Transport 29
Figure 2. PDMP inhibits
BFA-induced retrograde
membrane flow from Golgi
to ER in NRK cells. NRK fi-
broblasts, grown on cover-
slips, were incubated for 30
min at 378C in Hanks’ solu-
tion (control; A, G, and P) or
in Hanks’ containing 5 mg/ml
BFA (B, H, and Q), 100 mM
PDMP (C, K, and R), or both
BFA and PDMP (D, L, and
S). In E, M, and T, the 30-
min incubation with BFA 1
PDMP was preceded by a 30-
min incubation with PDMP,
while in F, N, and V, it was
preceded by a 30-min incuba-
tion with BFA. One series
(A–F) shows living cells (pre-)
incubated with C6-NBD-Cer
(see Materials and Methods).
In the other two series, cells
were fixed after the incuba-
tions with inhibitors and pro-
cessed for immunocytochem-
ical staining using antibodies
against ManII (G–N) or
GMPt-1 (P–V). Bar, 10 mm.The Journal of Cell Biology, Volume 142, 1998 30
precedes and is required for redistribution of Golgi mem-
branes into the ER compartment (Scheel et al., 1997).
When the distribution of the coatomer protein subunit
b-COP (Aridor and Balch, 1996; Bednarek et al., 1996)
was analyzed in PDMP- and BFA-treated NRK cells, it
turned out that its release from the Golgi complex, as in-
duced by BFA, was not prevented by PDMP (Fig. 5). Re-
gardless of whether BFA-treated cells were initially (Fig. 5
L) or simultaneously (Fig. 5 H) incubated with PDMP,
b-COP was released, indistinguishably from its release in
cells treated with BFA alone (Fig. 5 D). Note that release
of  b-COP occurred under conditions where the Golgi
complex did not disappear (Fig. 5, G and K), while PDMP
by itself did not affect the distribution of b-COP (Fig. 5 F,
compare with B and D).
PDMP Effect on BFA-induced Retrograde Golgi to
ER Membrane Flow Is Not Correlated to Inhibition of
SM Biosynthesis
A correlation between anterograde membrane transport
in the biosynthesis pathway and SM biosynthesis has been
suggested by Rosenwald et al. (1992) for CHO cells. Since
PDMP is known to affect sphingolipid metabolism in
other cell types as well (Radin et al., 1993), our results re-
garding inhibition of BFA-induced retrograde membrane
transport might be explained similarly. However, while
GlcCer biosynthesis is very sensitive to PDMP in all cell
types tested (Table I; c.f. Rosenwald et al., 1992), the ef-
fect of PDMP on SM biosynthesis is less drastic and, fur-
thermore, cell type dependent. In CHO cells, SM biosyn-
thesis is inhibited at PDMP concentrations above 40 mM
(Rosenwald et al., 1992), coinciding with concentrations
that impair anterograde VSV-G protein transport. In the
present work, using NRK cells, inhibition of SM biosyn-
thesis occurred with 100 mM PDMP (Table I). Yet in
HT29 G1 cells, no inhibition of SM biosynthesis was
found (Table I). In conclusion, PDMP had different ef-
fects on C6-NBD-SM biosynthesis in NRK and HT29 cells,
while in both cell types BFA-induced retrograde mem-
brane flow was inhibited. Therefore, these results argue
against a correlation between inhibition of BFA-induced
retrograde membrane flow and the biosynthesis of SM.
PDMP Inhibition of BFA-induced Retrograde Golgi
to ER Membrane Flow Is Not Mimicked by C6-Cer or 
Rescued by C6-GlcCer
Apart from an effect on the levels of GlcCer and SM,
PDMP treatment could result in an increase in Cer. The
latter has been correlated with an inhibition of protein
trafficking through the secretory pathway (Rosenwald and
Pagano, 1993). To establish whether the block in BFA-
induced retrograde membrane flow from Golgi to ER
could be attributed to an increase in Cer or a decrease in
GlcCer, the following experiments were performed. C6-
NBD-Cer–labeled HT29 G1 cells were initially incubated
with either C6-Cer or a combination of PDMP and C6-
GlcCer. This was done to mimic a possible increase in Cer
by PDMP or to compensate for the loss of GlcCer due to
treatment with the drug, respectively. If the action of
PDMP proceeded through changes in sphingolipid levels,
one could expect that C6-Cer mimicked the action of
PDMP or that the effect of the drug was counteracted by
supplying the cells with GlcCer. As shown in Fig. 6, this
was not the case, even at the high concentrations (100 mM)
Figure 3. Inhibition by PDMP of BFA-induced membrane flow
is reversible. NRK fibroblasts, grown on coverslips, were incu-
bated for 3 h at 378C in Hanks’ solution containing 100 mM
PDMP  1 5 mg/ml BFA (A). Alternatively, cells were in this solu-
tion for 30 min (B), followed by three Hanks’ washes and subse-
quent incubation with BFA alone for 1 (C) or 3 h (D). After
these incubations, cells were fixed and processed for immunocy-
tochemical staining using an antibody against ManII. Note that
discrete, swollen Golgi structures gradually disappear during the
BFA chase incubation. Bar, 10 mm.
Figure 4. Lyso-PDMP does not inhibit BFA-induced retrograde
membrane flow. HT29 G1 (A) or NRK (B) cells, grown on cov-
erslips, were incubated for 30 min at 378C in Hanks’ solution con-
taining 100 mM lyso-(d,l-threo-)PDMP, followed by another 30-
min incubation with lyso-PDMP 1 5 mg/ml BFA. In A, living
cells were incubated with C6-NBD-Cer as a Golgi stain, and the
image was taken with confocal scanning laser microscopy. In B,
after the incubations, cells were fixed and processed for immuno-
cytochemical staining using an antibody against ManII. The latter
image was taken with conventional fluorescence microscopy.
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of (nonfluorescent) short-chain sphingolipids that were
used. Incubation with 100 mM C6-Cer did not result in
preservation of discrete Golgi structures (Fig. 6, A and C)
during subsequent incubation with BFA, while the addi-
tion of C6-GlcCer did not result in loss of discrete Golgi
structures in PDMP-treated cells (Fig. 6, B and D). In con-
clusion, inhibition of BFA-induced retrograde membrane
flow does not appear to be correlated to changes in either
GlcCer or Cer levels.
C6-NBD-PDMP Is Localized in Endo/lysosomal 
Compartments, While It Affects Membrane Flow in the 
ER/Golgi System
To further investigate the mechanism of action of PDMP
Figure 5. PDMP does not interfere with BFA-induced release of
b-COP from Golgi. NRK fibroblasts, grown on coverslips, were
incubated for 30 min at 378C in Hanks’ solution (control; A and
B) or in Hanks’ containing 5 mg/ml BFA (C and D), 100 mM
PDMP (E and F), or both BFA and PDMP (G and H). In K and
L, the 30-min incubation with BFA 1 PDMP was preceded by a
30-min incubation with PDMP. After the incubations, cells were
fixed and processed for immunocytochemical double-staining us-
ing antibodies against ManII (A–K) and b-COP (B–L) in the
same cells. Polyclonal anti-ManII antibodies were visualized with
FITC anti–rabbit IgG F(ab9)2 fragments and monoclonal b-COP
antibodies with TRITC anti–mouse IgG F(ab9)2 fragments. Note
that PDMP does not interfere with BFA-induced b-COP release
(H and L) but does not cause release by itself (F). Bar, 10 mm.
Figure 6. Inhibition of BFA-induced retrograde membrane flow
is not mimicked by C6-Cer or counteracted by C6-GlcCer. HT29
G1 (A) or NRK (C) cells, grown on coverslips, were incubated
for 30 min at 378C in Hanks’ solution containing 100 mM C6-Cer,
followed by a 30-min incubation with 5 mg/ml BFA 1 C6-Cer. In
B (HT29) and D (NRK), cells were incubated during 30 min at
378C with 100 mM PDMP 1 100 mM C6-GlcCer, followed by a 30-
min incubation with BFA 1 PDMP 1 C6-GlcCer. In A and B, liv-
ing HT29 G1 cells were incubated with C6-NBD-Cer as a Golgi
stain, and images were taken with confocal scanning laser micros-
copy. In C and D, NRK cells are shown, which were fixed after
the incubation protocol and processed for immunocytochemical
staining using an antibody against ManII. The latter images were
taken with conventional fluorescence microscopy (C and D).
Bars,  10  mm.
Table I. Effect of PDMP on C6-NBD-Sphingolipid Biosynthesis
C6-NBD-GlcCer C6-NBD-SM
(percentage of
total C6-NBD-lipid)
(percentage of
total C6-NBD-lipid)
HT29 control 2.5 6 0.26 3.5 6 0.38
HT29 PDMP n.d.* 4.1 6 0.29
NRK control 1.9 6 0.15 10.3 61.3
NRK PDMP n.d.* 4.8* 6 0.35
Approximately 107 HT29 G1 or NRK cells were incubated for 60 min at 37°C with
10 mM C6-NBD-Cer in Hanks’ solution (control) or the same containing 100 mM D,L-
threo-PDMP. After these incubations, total C6-NBD-lipid (cell-associated 1 in the in-
cubation solution) was extracted, separated by HPTLC, and quantified (see Materials
and Methods). The biosynthesis of C6-NBD-GlcCer and C6-NBD-SM is expressed as
the percentage of total C6-NBD-lipid. Values are the means (6SD) of triplicate mea-
surements. Asterisks indicate values that are significantly different from control ac-
cording to student’s t test (P , 0.05).
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on membrane flow, we synthesized a fluorescent analogue
of the drug, C6-NBD-PDMP, enabling the study of uptake,
efflux, and intracellular localization of the drug. As shown
in Fig. 7 A, C6-NBD-PDMP was rapidly taken up by HT29
G1 cells. Incubation with 10 mM C6-NBD-PDMP for 30
min at 378C resulted in uptake of 1.58 pmol C6-NBD-
PDMP/nmol cellular lipid phosphorus (n 5 2), or 3.74 3
107 molecules/cell. This was 3.8% of the total amount of
C6-NBD-PDMP administered to the cells. Half of this up-
take was already achieved after 1.8 min (Fig. 7 A). Inter-
estingly, when the C6-NBD-PDMP–containing incubation
solution was removed and the cells were subsequently in-
cubated in fresh Hanks’ solution, a rapid efflux of C6-
NBD-PDMP occurred (Fig. 7 B). Half of the initial cell-
associated pool was released into the incubation solution
after only 40 s, while within 30 min 89% was released. The
residual intracellular pool remained constant during pro-
longed incubation up to at least 3 h (Fig. 7 B). TLC analy-
sis revealed that C6-NBD-PDMP was not metabolized to
lyso-PDMP and NBD-C6–fatty acyl chain during these in-
cubations (data not shown).
When HT29 G1 cells were incubated with 100 mM C6-
NBD-PDMP for 30 min at 378C, a staining pattern was ob-
served (Fig. 8 A), which is indicative of a primary localiza-
tion of the drug in endocytic organelles. This was further
examined by loading the cells with sodium dithionite. This
NBD fluorescence quencher is taken up into the endocytic
pathway by fluid-phase endocytosis and transported to en-
docytic compartments, including lysosomes. As a result,
the fluorescence of all NBD-labeled molecules residing in
endocytic compartments will be quenched (Kok et al.,
1995). When such an incubation was performed on cells
that had previously taken up C6-NBD-PDMP, intracellu-
lar fluorescence was quenched, as judged by confocal scan-
ning laser microscopy (Fig. 8 B). Indeed, when the extent
of NBD quenching was measured in a parallel experiment
with the same incubation protocol (see Materials and
Methods), 91.3% (65.6; n 5 3) quenching of C6-NBD-
PDMP was found. It should be noted that, given the ex-
perimental setup (see Materials and Methods), the pool of
C6-NBD-PDMP, which is quenched under these condi-
Figure 7. Uptake and efflux
of C6-NBD-PDMP by HT29
cells. (A) Approximately 107
HT29 G1 cells were incu-
bated with Hanks’ solution
containing 10 mM C6-NBD-
PDMP for various time inter-
vals at 378C. The incubation
solution was aspirated, and
the cells were washed with
Hanks’ solution. Thereafter,
the cells were subjected to
lipid extraction, followed by
TLC and scraping of C6-
NBD-PDMP spot. The fluo-
rescent PDMP was eluted
from the silica by shaking in
1% Triton X-100 and mea-
sured in a fluorimeter. Val-
ues are expressed as the per-
centage of uptake at 30 min
and represent the average of
duplicate measurements. (B)
Approximately 107 HT29
G1 cells were incubated
with Hanks’ solution containing 10 mM C6-NBD-PDMP for 30
min at 378C, followed by a chase in Hanks’ solution during vari-
ous time intervals. Finally, the incubation solutions and the cells
were separated and subjected to lipid extraction, followed by flu-
orescence measurement as described. Cell-associated C6-NBD-
PDMP after 30 min uptake and after various chase incubations is
expressed as the percentage of total fluorescence (i.e., cell-associ-
ated 1 excreted). Values are the means of duplicate measure-
ments.
Figure 8. Intracellular localization and effect of C6-NBD-PDMP.
HT29 G1 cells, grown on coverslips, were incubated for 30 min
at 378C in Hanks’ solution containing 100 mM C6-NBD-PDMP
(A). In B, this incubation was followed by a 30-min incubation
with Hanks’ containing 30 mM Na2S2O4. In a parallel experiment,
cells were incubated with 5 mM C6-NBD-Cer for 30 min at 378C,
followed by a 30-min incubation with Hanks’ containing 30 mM
Na2S2O4 ( C ). In all cases, the cells were subjected to a back-
exchange procedure at the end of the experiment. In D and E,
HT29 G1 cells were subjected to three subsequent incubations:
with 5 mM C5-Bodipy-Cer for 60 min at 378C; a 30-min incubation
with 100 mM C6-NBD-PDMP (D) or 5 mg/ml BFA (E); and a 30-
min incubation with 100 mM C6-NBD-PDMP 1 5 mg/ml BFA 1
30 mM Na2S2O4 (D and E). Images were taken with confocal
scanning laser microscopy. Bar, 10 mm.Kok et al. PDMP Blocks Golgi to ER Transport 33
tions, is the residual intracellular pool after large scale ef-
flux (see above). When HT29 G1 cells were labeled with
C6-NBD-Cer, followed by uptake of sodium dithionite,
Golgi labeling was readily observed (Fig. 8 C), indicating
that sodium dithionite did not acquire access to the Golgi
apparatus. Determination showed that in this case only
16.7% (66.9; n 5 3) quenching of NBD fluorescence oc-
curred. In conclusion, although the cell-biological effect of
PDMP is evidently associated with Golgi functioning, the
drug itself did not reach this organelle since C6-NBD-
PDMP could not be detected in the Golgi apparatus (c.f.
Rosenwald and Pagano, 1994).
An important question to be addressed was whether the
fluorescent derivative of PDMP inhibited BFA-induced
retrograde Golgi to ER membrane flow, similarly to na-
tive drug. HT29 G1 cells were incubated with C6-NBD-
PDMP (100 mM), followed by BFA treatment (Fig. 8 D,
c.f. to Fig. 1 E) or pretreated with BFA, followed by incu-
bation with C6-NBD-PDMP (Fig. 8 E, compare to Fig. 1 F).
To identify the Golgi in this case, the cells were prelabeled
with C5-Bodipy-Cer instead of C6-NBD-Cer. Concentra-
tion of C5-Bodipy-sphingolipids at the Golgi apparatus re-
sults in red fluorescence (Pagano et al., 1991), which can
be discriminated from the green NBD fluorescence of the
C6-NBD-PDMP. As shown in Fig. 8, D and E, C6-NBD-
PDMP was able to prevent BFA-induced Golgi–ER merg-
ing, provided that the fluorescent PDMP analogue was
added before BFA. Thus, C6-NBD-PDMP behaved simi-
larly to PDMP, in terms of inhibition of BFA-induced ret-
rograde membrane flow.
The PDMP Effect on BFA-induced Retrograde 
Membrane Flow in the ER/Golgi System Is Mimicked
by MK571
Recently, a correlation was established between the MDR
status of cells and the accumulation of glucosylceramides
(Lavie et al., 1996). Furthermore, agents that reverse mul-
tidrug resistance were shown to inhibit GlcCer synthase,
the target of PDMP (Lavie et al., 1997). In view of this
similarity in target, we examined whether such MDR-
reversing agents could also inhibit BFA-induced retro-
grade membrane transport. When HT29 G1 or NRK cells
were incubated with 50 mM MK571, a specific inhibitor of
multidrug resistance protein (MRP) function (Gekeler et
al., 1995), followed by incubation with BFA, discrete
Golgi structures were observed (Fig. 9, A and C). Thus,
similar to PDMP, this MRP-specific MDR-reversing agent
was able to block BFA-induced retrograde membrane
flow from the Golgi to the ER. MK571 also caused an inhi-
bition of GlcCer biosynthesis from C6-NBD-Cer, be it
much less efficient than PDMP. In comparison, in HT29
G1 cells 100 mM PDMP inhibited C6-NBD-GlcCer bio-
synthesis 34.7-fold (612.3; n 5 3), while 50 mM MK571
caused an inhibition of only twofold (60.4; n 5 3). MDR-
reversing agents acting primarily on P-glycoprotein (P-gp),
such as cyclosporin A and PSC833 (Friche et al., 1991; Wa-
tanabe et al., 1995), had no effect on C6-NBD-GlcCer bio-
synthesis (data not shown). In NRK cells, cyclosporin A
and PSC833 did not affect BFA-induced retrograde mem-
brane flow from Golgi to ER (Fig. 9 D). In HT29 cells,
both P-gp drugs showed some effect, although not as
prominent as MK571 (Fig. 9 B). Interestingly, when C6-
NBD-PDMP uptake was measured (as shown above) in
HT29 G1 cells, its cellular accumulation during a 10-min
incubation was increased to 140% (n 5 2) in the presence
of MK571, while cyclosporin A and PSC833 did not modu-
late its accumulation. The absence of effects of P-gp antag-
onists is compatible with results from Rosenwald and Pa-
gano (1994), showing that in CHO cells that were selected
for increased resistance to PDMP toxicity, this resistance
was not mediated by P-gp.
PDMP Modulates Calcium Homeostasis in HT29 Cells 
in at Least Three Different Ways
To explore the molecular mechanism behind the inhibiting
effect of PDMP on BFA-induced retrograde membrane
flow, we measured the intracellular calcium concentration
in HT29 cells and its potential modulation by PDMP. The
rationale for such experiments is rooted in the observa-
tions made by Ivessa et al. (1995), who reported that BFA-
induced retrograde membrane transport from Golgi to ER
depends on calcium homeostasis. When HT29 G1 cells
were incubated with PDMP, modulation of [Ca21]i was in-
deed observed (Fig. 10 A). The average basal [Ca21]i was
144 6 11 nM (n 5 78). Addition of 100 mM PDMP re-
sulted in a transient increase of 154 6 24 nM (n 5 8) above
basal [Ca21]i. The rise in [Ca21]i depended on the concen-
tration of PDMP (Fig. 11 A), with a modest increase ob-
served at 50 mM (22 6 12 nM; n 5 7) and a large enhance-
ment at 150 mM (445 6 70 nM; n 5 6). Below 50 mM,
responses were not observed, in accordance with the ab-
Figure 9. MK571 inhibits BFA-induced retrograde membrane
flow. HT29 G1 (A and B) or NRK (C and D) cells, grown on
coverslips, were incubated for 30 min at 37°C in Hanks’ solution
containing 50 mM MK571 (A and C) or 50 mM cyclosporin A (B
and D), followed by another 30-min incubation with the respec-
tive drugs 1 5 mg/ml BFA. In A and B, living HT29 G1 cells
were incubated with C6-NBD-Cer as a Golgi stain, and the im-
ages were taken with confocal scanning laser microscopy. In C
and D, after the incubations, NRK cells were fixed and processed
for immunocytochemical staining using an antibody against
ManII. The latter images were taken with conventional fluores-
cence microscopy. Bars, 10 mm.The Journal of Cell Biology, Volume 142, 1998 34
sence of effect on BFA-induced retrograde membrane
transport at these concentrations. Furthermore, in the
very same sample of cells, lyso-PDMP did not elicit any
Ca21 response, in contrast to PDMP (Fig. 10 B). This ob-
servation agrees well with the ineffectiveness of lyso-
PDMP regarding modulation of BFA-induced retrograde
membrane transport (Fig. 4).
A possible interaction between PDMP and receptor-
mediated [Ca21]i increases was subsequently studied using
extracellular ATP to stimulate P2 purinoceptors on the
plasma membrane of HT29 cells (Nitschke et al., 1993;
Zhang and Roomans, 1997). An ATP response could be
evoked after an initial PDMP response (Fig. 10 A). How-
ever, occasionally a very large increase in [Ca21]i was ob-
served after addition of 150 mM PDMP. Under these cir-
cumstances, the ATP response was completely abolished
(Fig. 10 D). The extent of inhibition of the ATP response
was dependent on the concentration of PDMP (Fig. 11 B).
Interestingly, with the reversed order of addition, PDMP
did still evoke a calcium response even after a very high
ATP response (Fig. 10 E). Next we analyzed the PDMP
response in terms of its components. In calcium-free me-
dium, 100 mM PDMP elicited a calcium response (Fig. 10
C), which was very similar to that in calcium-containing
medium (155 6 21 nM; n 5 7). In fact, at all concentra-
tions of PDMP, the two responses overlapped (Fig. 11 A),
indicating that the PDMP response can be attributed al-
most entirely to calcium release from intracellular stores,
with a minor contribution of influx from the medium. A
large part of the calcium release appeared to be associated
with the ER compartment since (a) the response is effec-
tively reduced after stimulation of the P2 purinoceptor by
ATP (Fig. 10 E), which releases calcium from the ER store
(c.f. Salter and Hicks, 1995; Liu et al., 1996), and (b) a sim-
ilar inhibition occurs after addition of thapsigargin (Fig. 10
G), a known blocker of the Ca21-ATPase present on the
ER (Lytton et al., 1991), which is followed by a PDMP
(100 mM) response of 23 6 4 nM (n 5 11) in calcium-free
medium. However, the observation that the PDMP re-
sponse could not be fully blocked by either ATP or thapsi-
gargin strongly suggests that PDMP released calcium from
another intracellular pool in addition to the ER. Finally, a
third component of the PDMP response was a striking in-
hibition of calcium influx, as induced by P2 purinoceptor
Figure 10. PDMP modulates calcium homeo-
stasis.  107 HT29 G1 cells/ml were loaded
with 2 mM indo-1/AM (see Materials and
Methods), followed by washing and dual-
wavelength measurement of fluorescence, us-
ing 106 cells/ml per measurement. [Ca21]i was
calculated as described. Single traces are
shown, which illustrate the following events:
(A) A moderate PDMP response (at 100 mM)
is followed by an ATP response (at 100 mM).
(B) Lyso-PDMP (at 100 mM) does not induce
a calcium response, while PDMP (at 100 mM)
does. (C) PDMP (at 100 mM) causes calcium
release from an intracellular store(s), as ob-
served in calcium-free medium. (D) A high
PDMP response (at 150 mM) abolishes the
ATP response (at 100 mM). (E) A high ATP
response (at 100 mM) is followed by a PDMP
response (at 100 mM). (F) PDMP (at 100 mM)
abolishes the secondary calcium influx com-
ponent of the thapsigargin response (at 1
mM). (G) PDMP (at 100 mM) still releases
calcium from an intracellular store after
thapsigargin-induced ER release (at 1 mM).Kok et al. PDMP Blocks Golgi to ER Transport 35
stimulation or thapsigargin treatment. As shown in Figs.
10 E and 11 B, PDMP blocked the sustained [Ca21]i in-
crease (influx) component of the ATP response. Further-
more, a drastic inhibition of the influx component of the
thapsigargin response occurred, as shown in Figs. 10 F and
11 C. In contrast to PDMP, none of the other calcium mo-
bilizing compounds ATP or thapsigargin or the Ca21 iono-
phore ionomycin were able to inhibit BFA-induced retro-
grade membrane transport from Golgi to ER in our
studies in HT29 and NRK cells (Fig. 12).
Discussion
Our results show that PDMP inhibits BFA-induced retro-
grade membrane flow from the Golgi apparatus to the ER,
since the drug impaired the transfer of both lipid and pro-
tein components of Golgi membranes to the ER in cells
treated with BFA. This reveals a novel action of PDMP, in
addition to its known effect on membrane transport
through the secretory pathway (Rosenwald et al., 1992).
Interestingly, with respect to its mechanism(s) of action,
PDMP neither directly counteracted the effect of BFA by
interference with the drug’s ability to induce release of
b-COP from Golgi membranes (c.f. Scheel et al., 1997), nor
exerted its effect by modulation of sphingolipid metabo-
lism. Rather, the data strongly support the view that the
PDMP-mediated impediment of membrane flow is accom-
plished via a specific modulation of calcium homeostasis.
Given the well-known effect of PDMP on sphingolipid
metabolism, we investigated a potential relation with
membrane transport. Rosenwald et al. (1992) have sug-
gested that the inhibition by PDMP of anterograde mem-
brane flow in the Golgi and from Golgi to the plasma
membrane is correlated to down-regulation of SM biosyn-
thesis. We do not favor this hypothesis as an explanation
for the effect of PDMP on BFA-induced retrograde mem-
brane flow because PDMP did not affect C6-NBD-SM bio-
synthesis in HT29 G1 cells while still inhibiting BFA-
induced retrograde membrane flow. PDMP is not likely to
exert its effect through changes in the levels of GlcCer or
Cer either. A rise in the cellular Cer level by exogenous
addition of C6-Cer did not mimic the effect of PDMP on
BFA-induced retrograde membrane flow. Exogenous ad-
Figure 11. PDMP modula-
tion of [Ca21]i and ATP-
induced [Ca21]i increase is
concentration dependent.
107 HT29 G1 cells/ml were
loaded with 2 mM indo-1/AM
(see Materials and Meth-
ods), followed by washing
and dual-wavelength mea-
surement of fluorescence, us-
ing 106 cells/ml per measure-
ment. [Ca21]i was calculated
as described. In A, the [Ca21]i
increase is shown as a func-
tion of the PDMP concentra-
tion. In B, the ATP (100
mM)-induced [Ca21]i increase
after pretreatment with
PDMP is shown as a function
of the PDMP concentration.
circles, total response; trian-
gles, response in calcium-free
medium; squares, calcium in-
flux after t 5 3 min. C shows
the effect of 100 mM PDMP
on the secondary calcium in-
flux component of the thapsi-
gargin (1 mM) response (c.f.
Fig. 10 F). Data are the means 6 SEM of four to eight indepen-
dent measurements.
Figure 12. Thapsigargin, ionomycin, and ATP do not inhibit
BFA-induced retrograde membrane flow. HT29 G1 (A–C) or
NRK (D–F) cells, grown on coverslips, were incubated for 30 min
at 378C in Hanks’ solution containing 1 mM thapsigargin (A and
D), 100 nm (HT29 G1) or 1 mM (NRK) ionomycin (B and E), or
100 mM ATP (C and F). This was followed by another 30-min
incubation with the respective drugs 1 5 mg/ml BFA. In A–C, liv-
ing cells were incubated with C6-NBD-Cer as a Golgi stain, and
the images were taken with confocal scanning laser microscopy.
In D–F, after the incubations, NRK cells were fixed and pro-
cessed for immunocytochemical staining using an antibody
against ManII. The latter images were taken with conventional
fluorescence microscopy. Bars, 10 mm.The Journal of Cell Biology, Volume 142, 1998 36
dition of C6-GlcCer, which would compensate for the loss
of cellular GlcCer, did not counteract the effect of PDMP.
Furthermore, at concentrations below 50 mM, PDMP did
not affect BFA-induced retrograde membrane flow but
still inhibited GlcCer biosynthesis efficiently (data not
shown). In conclusion, the inhibition of membrane flow
does not appear to be correlated to fluctuations in sphin-
golipid levels.
MDR inhibitor studies were prompted by recent obser-
vations on the correlation between GlcCer biosynthesis
and MDR (Lavie et al., 1996, 1997). Our own observations
regarding the fast kinetics of C6-NBD-PDMP efflux from
HT29 cells and its specific modulation by the MRP inhibi-
tor MK571 suggested involvement of MRP pumps in the
action of PDMP on membrane transport. Although a spe-
cific effect of MK571 (in contrast to the P-gp inhibitors cy-
closporin A and PSC833) on BFA-induced retrograde
membrane transport was revealed, this experimental ap-
proach did not provide insight into the mechanism of ac-
tion of PDMP. Nevertheless, a correlation with sphin-
golipid metabolism was again refuted, given the efficient
inhibition of BFA-induced retrograde membrane flow by
MK571 at a concentration of 50 mM, whereas the effect on
GlcCer biosynthesis was marginal compared with PDMP.
More insight into the underlying mechanism of action of
PDMP was obtained when modulation of calcium homeo-
stasis by PDMP was investigated, inspired by results from
Ivessa et al. (1995), who showed that redistribution of the
Golgi complex into the ER is linked to calcium homeosta-
sis in NRK and HeLa cells. An intracellular calcium re-
sponse was indeed triggered by PDMP, in a similar con-
centration range as observed for the occurrence of
inhibition of BFA-induced retrograde transport (both
starting at 50 mM PDMP), while lyso-PDMP served as a
negative control regarding both intracellular calcium re-
sponses and modulation of BFA-induced retrograde mem-
brane transport. With respect to the low intracellular cal-
cium response at 50 mM PDMP, it should be noted that
measurements were performed at room temperature (to
avoid compartmentalization of indo-1), which may give
rise to an underestimation of the responsiveness at 378C.
Furthermore, as will be pointed out, the absolute size of
the calcium response does not appear to be critical. Ivessa
et al. (1995) reported that drugs affecting calcium equilib-
rium, such as thapsigargin and ionomycin, inhibited retro-
grade membrane transport in the ER/Golgi system in
BFA-treated cells. In the present work, we have obtained
evidence indicating that a more specific modulation of cal-
cium homeostasis is involved. In our studies in HT29 and
NRK cells, ATP, thapsigargin, and ionomycin did not in-
hibit BFA-induced retrograde transport, suggesting that
membrane transport is not associated with calcium release
from the ER pool but rather is linked to a specific calcium
event. Our detailed analysis of the components of the cal-
cium response to PDMP indicates that in addition to the
ER, another PDMP-sensitive calcium pool exists. We have
not yet characterized this pool, but it appears to be differ-
ent from the recently described thapsigargin- and inositol-
1,4,5-trisphosphate–insensitive calcium pool (Pizzo et al.,
1997), since the latter is ionomycin sensitive. Thus, the size
of the calcium response to PDMP, which is mostly deter-
mined by the ER release component, is not critical for
membrane transport inhibition. Rather, the intracellular
localization of the PDMP-sensitive, thapsigargin- and
ATP-insensitive calcium pool is likely to be relevant. This
pool may function in concert with the shutdown of calcium
influx from the medium, as induced by PDMP, constituting
the basis of the observed inhibition of BFA-induced mem-
brane transport. A contribution of calcium influx inhibi-
tion to the effect of PDMP on membrane transport appears
likely given the slow kinetics of reversibility of membrane
flow inhibition (Fig. 3). In this respect, it was found that af-
ter a single administration of PDMP to cells calcium influx
inhibition persisted for at least 2 h (data not shown). The
persistent presence of a (C6-NBD-)PDMP pool of about
13% (Fig. 7 B) correlates well with the persistent effect of
PDMP on membrane flow and calcium influx inhibition.
Supporting evidence for an indirect mode of action of
PDMP, i.e., not related to its interference with sphin-
golipid metabolism in the Golgi apparatus, includes: (a)
PDMP acts very quickly, as observed when PDMP, added
to cells 3 min after the addition of BFA, still inhibited
BFA-induced retrograde membrane transport; only when
the preincubation with BFA was extended to 10 min could
PDMP not prevent merging of Golgi with ER (data not
shown). These results are compatible with modulation of a
fast acting Ca21 signaling system within the cell. A prereq-
uisite is its rapid uptake into the cell, which was shown to
occur using a fluorescent derivative of PDMP (C6-NBD-
PDMP; Fig. 7 A). (b) C6-NBD-PDMP was largely found in
endocytic compartments (c.f. Rosenwald and Pagano,
1994), while the fraction residing in the Golgi was too
small to be discerned by confocal scanning laser micros-
copy. It should be noted that the fluorescent analogue of
PDMP was as effective as the native drug in causing mem-
brane flow inhibition, ruling out possible artifacts of fluo-
rescent derivatization. Chase experiments revealed that
two pools of C6-NBD-PDMP could be discerned after 30
min incubation with the drug, one of which was rapidly ex-
creted, the other being very stable (Fig. 7 B). Also, this
stable pool was residing primarily in endocytic compart-
ments since it was almost completely quenched by sodium
dithionite. These results show that C6-NBD-PDMP could
not be detected in the Golgi apparatus, and thus indicate
the unlikeliness of a direct effect of PDMP on Golgi mem-
brane structure or Golgi membrane proteins involved in
transport. A general disrupting effect of PDMP on mem-
brane structure can also be excluded given the transient
nature of the intracellular calcium response to PDMP,
since a sustained influx would be expected in case of mem-
brane disruption.
All our experiments concerning the effects of PDMP on
retrograde membrane flow from Golgi to ER were per-
formed in the context of BFA treatment. Therefore, no
conclusions can be drawn with respect to the effect of
PDMP on retrograde membrane flow under physiological
circumstances, i.e., without BFA, a pathway that functions
in the delivery of Golgi- and plasma membrane–localized
proteins to the ER (Johannes et al., 1997; Cole et al.,
1998). In this respect, PDMP has recently been shown to
shift the steady-state distribution of infectious bronchitis
virus M protein and ERGIC-53 from the Golgi to the ER
in BHK cells under conditions not involving BFA
(Maceyka and Machamer, 1997). However, the GolgiKok et al. PDMP Blocks Golgi to ER Transport 37
stack markers ManII and giantin were not redistributed,
indicating that this effect of PDMP was related to cycling
of specific proteins rather than to overall membrane flow.
This effect of PDMP was attributed to Cer accumulation,
although it was neither completely reversed by metabolic
inhibitors of Cer formation nor mimicked by exogenous
C6-Cer addition.
We propose two models for the mechanism by which
PDMP and PDMP-induced [Ca21]i changes could inhibit
BFA-induced retrograde membrane flow. (a) PDMP acts
independently of BFA in a process (e.g., the actual fusion
process) involved in the merging of ER and Golgi mem-
branes during the direct, vesicle budding-uncoupled fusion
reaction. (b) PDMP specifically antagonizes one of the ac-
tions of BFA. Clearly, PDMP does not act by interference
with BFA-induced release of b-COP (Fig. 5). This is con-
sistent with observations from Ivessa et al. (1995), who
showed that calcium mobilizing agents that prevent BFA-
induced retrograde membrane flow did not interfere with
b-COP release. This shows that although BFA-induced
dissociation of coatomer from membranes is required for
redistribution of Golgi membranes into the ER (Scheel
et al., 1997), it is not sufficient. In this respect, it has re-
cently been shown in permeabilized cells that in the ab-
sence of NAD1, BFA can dissociate coatomer from the
Golgi complex without affecting the structure of the or-
ganelle (Mironov et al., 1997). NAD1- and BFA-depen-
dent ADP-ribosylation of BARS-50 was shown to play a
role in the Golgi disassembling activity of BFA. On the
other hand, it cannot be excluded that PDMP (partly) ex-
erts its effect by detoxification of BFA, as has been shown
to occur for forskolin (Nickel et al., 1996), an activator of
adenylyl cyclase, which also inhibits BFA-induced retro-
grade membrane flow (Lippincott et al., 1991). However,
we consider this possibility unlikely, given the fast kinetics
of PDMP action (no preincubation with PDMP is required
to obtain inhibition of BFA-induced retrograde mem-
brane flow; even addition of PDMP 3 min after BFA is ef-
fective), compared with the kinetics of secretion of BFA
conjugates.
In conclusion, PDMP inhibition of BFA-induced retro-
grade membrane flow in the ER/Golgi system is dissociated
from its well-known effect on glycosphingolipid metabolism
and does not involve direct interference with the integrity of
Golgi membranes. Rather, it appears to be related to spe-
cific modulation of calcium homeostasis, a novel action of
the drug, and mimicked by a specific antagonist of the MRP
pump. Thus, PDMP is a novel tool to interfere with BFA-
induced retrograde Golgi to ER membrane transport and
provides new insights into the physiological mechanisms
underlying this process. Future work will aim at further
identification of PDMP-sensitive calcium pools and the
assessment of the role of these pools and calcium influx in-
hibition in membrane transport between Golgi and ER.
Furthermore, we will investigate whether the effects of
PDMP on BFA-induced retrograde membrane transport
are a reflection of inhibition of retrograde transport under
physiological circumstances (e.g., without BFA).
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